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Abstract 
 
Purpose. Complete Signal Transducer and Activator of Transcription 1 (STAT1) deficiency is a 
rare autosomal recessive condition characterized by impairment of intracellular signaling from both 
type I and type II interferons (IFN). Affected patients are prone to early severe mycobacterial and 
viral infections, which usually result in death before 18 months of age. We previously reported a 
patient affected by complete STAT1 deficiency who underwent hematopoietic stem cell 
transplantation (HSCT). Here we describe the transplantation procedures and long-term outcomes. 
Methods. The patient, who had suffered multiple life-threatening mycobacterial and viral infections 
in the first years of life, underwent HSCT at 4 years of age from a partially-matched (HLA 
compatibility 8/10) unrelated donor after a myeloablative conditioning regimen consisting of 
busulfan, cyclophosphamide, and anti-thymocyte globulin.  
Results. Hematological reconstitution was detected at d+15, with full donor engraftment 
demonstrated by molecular analysis of leukocytes. Several complications occurred in the post-
transplantation phase, including acute graft versus host disease, posterior reversible encephalopathy, 
thrombotic thrombocytopenic purpura, bilateral keratoconjunctivitis with complete loss of vision, 
and chronic lower limb lymphedema. Analysis of STAT1 in CD3+ cells at 90 and 120 days after 
HSCT by flow cytometry showed normal STAT1 phosphorylation levels in response to IFN-α. 
Conclusions. Notably, no severe infections occurred after discharge (day +90) during a 9-year 
follow-up, suggesting that normal response to IFNs in hematopoietic cells is sufficient to provide 
protection in humans. 
 
 
 
Keywords: hematopoietic stem cell transplantation, STAT1 deficiency, primary immunodeficiency, 
signaling 
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Introduction 
 
Signal Transducer and Activator of Transcription 1 (STAT1, encoded by STAT1 gene) is an 
intracellular protein which has a fundamental role in signal transduction from both type I (IFN-α 
and IFN-β) and type II (IFN-γ) interferons (IFNs), and is therefore involved in immune response to 
virus and other intracellular pathogens [1,2]. STAT1 deficiency is a genetic condition characterized 
by a heterogeneous clinical phenotype [3,4]. Partial deficiency of STAT1 may be inherited in an 
autosomal recessive or dominant manner. Partial-recessive STAT1 deficiency is characterized by 
reduced expression of STAT1 leading to decreased but not abolished transcription of type I and 
type II IFN-induced genes. This condition is associated with increased susceptibility to severe but 
curable intracellular bacterial and viral diseases [5,6].  
Partial-dominant STAT1 deficiency is characterized by impaired IFN-γ signaling but normal 
response to type I IFN, leading to increased susceptibility to infections by weakly virulent 
mycobacteria as well as by Salmonella spp. but not to viral infections, thus representing one of the 
causes of Mendelian Susceptibility to Mycobacterial Diseases (MSMD) [7–10]. Complete STAT1 
deficiency, on the other hand, is an autosomal recessive condition that results in complete functional 
impairment of STAT1-dependent interferon response (both type I and II) [11,12]. Affected patients 
are prone to early fatal mycobacterial and viral infections. So far, only six patients from four 
unrelated families with complete STAT1 deficiency have been reported, including the present one. 
All patients, apart from the present one, died before 18 months of age from mycobacterial or viral 
infections [3]. In one case, hematopoietic stem cell transplantation (HSCT) was attempted, 
however, the patient died of multiorgan failure associated with Epstein Barr Virus (EBV) infection, 
three months after transplantation [12].  
We previously reported a patient who carried a novel homozygous mutation affecting a splicing site 
of the STAT1 gene, leading to exon 3 skipping and to synthesis of a lower molecular weight STAT1 
protein.[13] Functional characterization revealed marked reduction of STAT1 phosphorylation, and 
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a complete defect of DNA-binding activity, resulting in complete impairment of peripheral blood 
mononuclear cell (PBMCs) functional response to both IFN-γ and IFN-α, as well as partial 
impairment of NK functional activity. Here we report the clinical course and outcome of HSCT in 
this patient, demonstrating for the first time that HSCT may be an effective option for treatment of 
complete STAT1 deficiency. 
 
Methods 
Flow cytometry. PBMCs were obtained from heparinized blood by Ficoll-Hypaque centrifugation 
after obtaining informed consent from the patient’s parents. Cells were left unstimulated or 
stimulated with IFN-α (40000U/ml for 30 minutes) and were stained simultaneously using a 
fluorescein isothiocyanate (FITC)-conjugated mouse anti-CD3 IgG mAb. Cells were fixed and 
permeabilized, according to the BD protocol (Protocol III), and stained with phycoerythrin (PE)-
conjugated mouse anti-pSTAT1-Tyr-701 (BD Pharmigene) or isotype-matched mAb PE (BD 
Bioscence). Cells were analyzed by flow cytometry after gating CD3+ cells by FACSCalibur flow 
cytometer (BD Bioscence) and analyzed by the FlowJo version 7.5 Software (TreeStar). The extent 
of STAT1 phosphorylation was calculated as Mean Fluorescence Intensity (MFI).   
Real Time PCR. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Valencia, 
CA, USA) according to the manufacturer’s instructions. For the RT-PCR analysis, Assays-on-
DemandTM Products and Taqman Master Mix from Applied Biosystems were used according to the 
instruction manual to analyze STAT1, IFNγ, IL2RA, SOCS1,SOCS3, and GAPDH gene expression. 
Target gene expression was normalized to the housekeeping gene (GAPDH) expression and 
presented as n-fold increase over those in the  healthy control  by using 2-∆∆CT  evaluation. 
 
Results 
Here we describe a male patient born at term via an uncomplicated cesarean section from 
consanguineous parents who were originally from Pakistan. His father harbored a balanced 
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chromosomal translocation of uncertain clinical significance [46XY, t(6;11) (q27; q14.3)]. His 
mother’s karyotype was normal. An older brother, who had a multiple malformative syndrome of 
unknown etiology (including brain, skeletal, anorectal, and renal anomalies), died at nine months of 
age from respiratory failure. Two previous pregnancies resulted in stillbirth. Notably, the mother 
reported that five of her brothers died in infancy, from unspecified causes. As previously described, 
from 10 months of age our patient developed several life-threatening infections (Table 1) [13]. All 
standard immunological evaluations performed in the first years of life, including lymphocyte 
subsets analysis, response to mitogens, T-Cell receptor excision circles (TRECs) and K-deleting 
recombination excision circles (KRECs) counts, serum immunoglobulins, antibody response against 
vaccine antigens, DHR-123 testing for chronic granulomatous disease, and CD11b/CD18 
expression were normal. However, PBMCs response to IFN-γ showed defective production of 
tumor necrosis factor (TNF) alpha. Genetic analysis of STAT1 gene revealed a homozygous 
mutation inherited from heterozygous parents (372G>C), resulting in exon 3 skipping and synthesis 
of a lower molecular weight STAT1 protein. Further functional and molecular characterization of 
this defect has been previously reported elsewhere.[13] 
At the age of 4 years and 7 months the patient underwent HSCT from a partially-matched unrelated 
donor (MUD). HLA compatibility was 8/10 (HLA-C mismatch)). Pre-procedure testing showed a 
low number of CMV copies (500/mL) and absent Epstein Barr Virus (EBV). CMV infection was 
successfully treated with ganciclovir. Blood testing of the donor showed normal immunoglobulin 
response against HSV, CMV and EBV, suggesting normal immunization against herpetic viruses. A 
myeloablative conditioning regimen was used, including busulfan 5 mg/kg/day on day (d)–10 to d–
7, cyclophosphamide 50 mg/kg/day on d–6 to d–3, and anti-thymocyte globulin 2.5 mg/kg/day on 
d–6 to d–3. Graft versus host disease (GVHD) prophylaxis included cyclosporine 5 mg/kg/day from 
d–1. On the day of transplantation, the patient received 1.87 x 109 cells from erythrocyte-depleted 
marrow (3.93 x 106 CD34+ cells/kg, 35.17 x 106 CD3+/kg). Because of AB0 incompatibility 
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between patient (B+ before HSCT) and donor (A+), on d+10 he developed Coombs-positive 
hemolytic anemia, which required intravenous methylprednisolone therapy at 5 mg/kg.  
Hematological reconstitution was detected at d+15, with full donor engraftment demonstrated by 
molecular analysis of leukocytes. Hematological reconstitution was associated with acute grade III 
cutaneous and intestinal GVHD, requiring an increase of methylprednisolone therapy at 10 mg/kg 
for three days. On d+20, he developed severe bilateral ulcerative keratoconjunctivitis, resulting in 
corneal scarring and complete loss of vision. Tests for viral pathogens were negative. On d+35 
rituximab therapy was started following the detection of EBV in blood (358 copies/mL). Treatment 
was associated with generalized status epilepticus. Computed tomography demonstrated bilateral 
subcortical hypodense areas, consistent with posterior reversible encephalopathy syndrome (PRES). 
On d+53 thrombotic thrombocytopenic purpura developed, with severe anemia (6.2 g/dL), 
thrombocytopenia (5000/mL) and peripheral schistocytes. Defibrotide infusions and repeated 
plasmaphereses were performed, while mycophenolate mofetil (MMF) was started and cyclosporine 
was stopped.  
Analysis of STAT1 phosphorylation in response to IFN-α (40000U/ml for 30 minutes) in CD3+ 
cells at 90 and 120 days after HSCT by flow cytometry as compared to pSTAT1 levels in response 
to IFN-α before HSCT showed normal STAT1 phosphorylation levels in response to the cytokine 
already at day +90 (Figure 1), suggesting a normal reconstitution of STAT1 signaling in 
lymphocytes. Functional studies of PBMC response to cytokines signaling through STAT1  
revealed normal upregulation of MXA and STAT1 mRNAs in response to IFN-α  (1000 U/ml) and 
TNFA and IDO mRNAs in response to  IFN-γ  (1000 U/ml). 
On d+90 the patient was discharged from the bone marrow transplantation unit, in good general 
condition and without signs of GVHD. MMF was discontinued. On d+112 III grade cutaneous 
GVHD relapsed on palms and soles, and was successfully treated increasing prednisone, restarting 
oral MMF, and applying topical tacrolimus. Ten months after HSCT, he developed progressive left 
lower limb edema. An uncertain history of trauma to the left knee was present. Ultrasonography 
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showed post-phlebitis changes in the left common femoral vein and in the external iliac vein. In the 
following months, he developed progressive swelling of both lower limbs as well as of the scrotal 
sac and the penis, which was ultimately attributed to bilateral lymphedema. Compressive stockings 
were proposed, with only partial benefit. Follow-up ophthalmologic evaluations confirmed 
complete loss of vision, secondary to bilateral vascularized corneal leukoma.  
Child growth was normal until 4 years of age (high 109.5 cm, 75-90° percentile, weight 6.7 kg, 25-
50° percentile). It briefly declined shortly after HSCT (5.5 years height 110.4 cm, 25-50° percentile, 
weight 157 kg 3-10° percentile). However, his growth returned to normal in the following years (at 
13 years of age; height 160.7 cm, 75-90° percentile; weight 41.2 kg, 25-50° percentile).  
At the last available follow up visit, performed at 13 years of age, he was in good general condition, 
although he still suffered from complete blindness and bilateral lower limbs lymphedema. Complete 
blood count and lymphocytes subsets were within normal limits, as well as TRECs, KRECs, and 
lymphocyte proliferative response to mitogens. Serum immunoglobulins were within normal levels. 
Protective antibody response against vaccine antigens was documented. Molecular evaluation of 
neutrophils and lymphocytes confirmed full donor chimerism. Notably, no severe infections 
occurred after discharge from transplantation unit following HSCT. 
 
Discussion 
We report the outcome of a patient with complete functional absence of STAT1 who underwent 
HSCT from an unrelated donor. To our knowledge, this is the first patient to be successfully cured 
from this condition. Like other patients with complete STAT1 deficiency, the clinical course of our 
patient prior to HSCT was characterized by severe viral and mycobacterial infections, suggesting 
the necessity of HSCT. A previous report by Chapgier et al. had not shown favorable outcome after 
HSCT in another patient with complete STAT1 deficiency [12]. This patient had received HSCT 
from matched sibling donor at 8 months of age after a conditioning regimen with alemtuzumab, 
fludarabine, and melphalan, plus prednisolone and tacrolimus for GVHD prophylaxis. Engraftment 
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in this case was slow and likely incomplete, since CD3+ count 2.5 months after HSCT was low 
(300/µL), and regular platelet transfusions were required. At 70 days post-transplantation, he 
developed EBV infection associated with respiratory failure. Despite treatment with rituximab and 
donor T cell infusions resulting in EBV clearance, the patient eventually died from multiorgan 
failure at 91 days post-transplant. 
HSCT in our patient was performed after a myeloablative conditioning regimen using busulfan and 
cyclophosphamide, while in the patient reported by Chapgier et al. a reduced-intensity conditioning 
regimen was adopted. While reduced-intensity regimens are commonly used in HSCT for immune 
deficiencies, this may have increased the risk of graft failure. A clear recommendation on which 
regimen to adopt in these patients cannot be made from our limited experience. The post-transplant 
clinical course in our patient was characterized by multiple and severe complications, including 
Coombs-positive hemolytic anemia, acute grade III cutaneous and intestinal GVHD, rituximab-
associated PRES, thrombotic thrombocytopenic purpura (HSCT-related thrombotic 
microangiopathy), bilateral keratoconjunctivitis, and bilateral lower limb lymphedema, resulting in 
long-term disabilities. It is not clear whether the observed complications may have been influenced 
by the patient’s genetic condition. Nevertheless, considering also the experience by Chapgier et al., 
it may be prudent to consider these patients at high risk of complications during HSCT. Partial 
HLA-mismatch (8/10) has probably contributed to the development of cutaneous and intestinal 
GVHD, while keratoconjunctivitis and lower limb lymphedema have an uncertain cause. 
Interestingly, lymphedema predisposition has been observed in patients with GATA2 mutations 
associated with Emberger syndrome, a disorder characterized susceptibility to myelodysplastic 
syndrome/acute myeloid leukemia (MDS/AML) [14,15]. In this condition, GATA2 loss of function 
mutations can affect the transcription of genes involved in lymphatic vessel valve development, 
resulting in predisposition to lymphedema [16]. Although STAT1 loss of functions mutations have 
never been linked to risk of lymphedema, cytokines signaling trough STAT1, such as IL-27, can 
regulate lymphatic endothelial cell proliferation [17]. 
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In our patient HSCT allowed durable, long-term full donor chimerism as well as full immunological 
reconstitution, with normalization of STAT1 phosphorylation in lymphocytes, as demonstrated by 
flow cytometry. STAT1 is required for IFN response both in hematopoietic cells as well as in other 
cell types (e.g. epithelial cells) following intracellular and viral infections. In mice, lack of both 
type I and type III IFN-mediated signaling only in epithelial cells but not in hematopoietic cells 
results in lethal infection by influenza virus [18]. HSCT transplantation has been effective in our 
patient in the correction of the genetic defect in hematopoietic cells, while it could not have any 
effect on STAT1 deficiency in epithelial or endothelial cells. Remarkably, our STAT1-deficient 
patient did not present evidence of susceptibility to viral infections after receiving HSCT, 
suggesting that immune response against viral infections might be more redundant in the human 
system as compared to mice, since normal IFN response in hematopoietic cells but not in the 
epithelia may be sufficient to provide protection. 
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Table 1 
 
Infectious diseases prior to HSCT. 
 
Age Events 
10 months Severe disseminated Mycobacterium kansasii infection, possibly 
associated with Aspergillus fumigatus co-infection 
16 months Laryngitis and pulmonary infection of unknown etiology with right 
upper lobe atelectasis 
17 months Right lung pneumonia, unidentified agent 
20 months Acute infectious mononucleosis complicated by cutaneous Herpes 
simplex infection 
23 months CMV pneumonia  
25 months Sepsis from an unidentified microbial agent, associated with 
refractory seizures 
27 months Pneumonia from unknown agent 
35 months CMV pneumonia 
4 years Enterovirus meningitis complicated by cerebral venous sinus 
thrombosis. No persistent neurological disabilities were present at 
recovery, brain MRI showed multiple subarachnoid liquoral 
collections and mild hydrocephalus from aqueductal stenosis 
 Lymphocyte subsets: lymphocytes 11,634 cells /µl; CD3 81,5%; CD4 
30,7%; CD8 43,4%; CD4/CD45RA 14,7%; CD4/CD45R0 11,4%; 
CD19 14%; CD16 4,9%. 
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Figure legend 
 
Figure 1. Functional reconstitution of STAT1 mediated signaling after bone marrow transplantation.  
We performed flow cytometric analysis of STAT1 phosphorylation (Y701) of peripheral blood 
CD3+ cells after treatment with IFN-α (40000U/µl) or medium alone for 30 minutes at 37°C using 
intracellular staining with an anti-phospho-STAT1-PE before HSCT (panels A) and 8 years after 
HSCT (panels B) in healthy donor (left panels) and patient (right panels). Functional response to 
IFN-α (panels C) and IFN-γ (panels D) were evaluated by stimulation of PBMCs from a healthy 
donor and from patient, 8 years after HSCT, for 24 hours. MXA and STAT1 mRNAs upregulation in 
response to IFN-α (1000 U/ml) and TNFA and IDO mRNAs in response to IFN-γ (1000 U/ml) were 
measured by real time PCR. 
